Concord Biotech IPO Allotment Status, Check Allotment on Linkintime

By Jagat Joshi
August 14, 2023

Concord Biotech IPO Allotment Status is to be finalized on August 11, 2023. The refund will be initiated on August 14 and the shares will be credited to the Demat account on August 16. Concord Biotech IPO to list on August 17. The IPO investors can check their Concord Biotech IPO allotment status online on the Linkintime website or they can check it via their bank account and Demat login as offline mode. Check out here step to step guide from where you can check Concord Biotech IPO allotment status online or offline.

Concord Biotech IPO subscribed 24.86 times overall in that QIB is 67.67 times, NII is 16.99 times, and 3.78 times in Retail. Concord Biotech IPO to raise around ₹1551 Crores via IPO. The price band is fixed at ₹705 to ₹741 per equity share. The IPO is to list on BSE and NSE.

Basis of Concord Biotech IPO Allotment:

Based on the retail subscription the Concord Biotech IPO basis of allotment will be around 15:4 (Approx).

Concord Biotech IPO Allotment Links (Allotment Out)

Linkintime:	Linkintime IPO Allotment Page
IPO Watch:	IPO Allotment Status Page

#Step 1: How to check Concord Biotech IPO Allotment Status on Linkintime?

Log on to Concord Biotech IPO allotment page – Linkintime.com
Select IPO Name ‘Concord Biotech‘ from the drop-down menu bar
Select Option from PAN Number, application Number, or DP ID Option
As per selection add PAN Number, application Number, or Demat Account Number
Click on the ‘Search’ Button
You will be able to see your Concord Biotech IPO allotment status on the screen (mobile/desktop).

#Step 2: How to check Concord Biotech IPO Allotment Status in Demant Account?

Call Your Broker or Login to Your Demat Account / Trading Account
Check whether the stock is credited to your account or not
If you got the allotment the credited shares will appear in the Demat account

#Step 3: How to check Concord Biotech IPO Allotment Status in Bank Account?

Login to your Bank Account from which you applied the Concord Biotech IPO
Check the Balance Tab
If you got the allotment the Amount will be debited
If you did not get the allotment the Amount will be released
If you got the allotment you got an SMS “Dear Customer, Bank Name Account 00001 is debited with INR 00000.00 on Date. Info: IPOName. The Available Balance is INR 000000.”

Note: Concord Biotech IPO Registrar is responsible for the IPO allotment and refund process. If you have any queries regarding the Concord Biotech IPO Allotment date and time please contact the registrar with your queries.

Concord Biotech IPO Allotment Status FAQs

When is Concord Biotech IPO Allotment Date?

Concord Biotech IPO Allotment is to be available on August 11, 2023.

What will be Concord Biotech IPO Refund Date?

The IPO refund date is August 14, 2023.

What is the chance to get the Concord Biotech IPO Allotment?

The IPO allotment is based on the subscription. As per the retail application received the basis of allotment will be around 15:4.

How to check the Concord Biotech IPO Allotment Status?

Check Concord Biotech IPO allotment status via your PAN number, the application number, or the amount deducted in your bank.

How to check the Concord Biotech IPO Allotment via Registrar?

Just log on to the Concord Biotech IPO Allotment page here: Click Here and Check via application Number, PAN Number of your Demat Account Number. It is Easy Right!

What is Concord Biotech IPO Listing Date?

Concord Biotech IPO listing date is August 18, 2023. The IPO is to list on BSE and NSE.

Follow IPO Watch for the Upcoming IPO news and their reviews, also keep following us on Twitter, Facebook, and Instagram. For our latest videos, subscribe to our YouTube channel.

Read Also:

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.